CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT
APPROVAL OF CLINICAL TRIAL APPLICATION FOR OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE MONOHYDRATE NASAL SPRAY BY THE NMPA

This announcement is made by CF PharmTech, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the latest research and development of the Group.

INTRODUCTION

Reference is made to the announcement dated December 17, 2025. The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the clinical trial application (the "**CTA**") for olopatadine hydrochloride and mometasone furoate monohydrate nasal spray (the "**Product**"), has been approved by the National Medical Products Administration of the People's Republic of China ("**NMPA**"). The Company is the first in China to submit a generic clinical trial application for this Product. The relevant information is hereby announced as follows:

Product name	:	Olopatadine hydrochloride and mometasone furoate monohydrate nasal spray
Application type	:	Clinical trial application for domestic drug registration
Acceptance number	:	CYHL2500215/CYHL2500214
Applicant	:	The Company
Proposed Indication	:	Treatment of moderate-to-severe allergic rhinitis in adults and children aged 12 and older

The Product combines an antihistamine and a corticosteroid into a single formulation. It focuses on the unmet needs of patients with moderate-to-severe allergic rhinitis (AR), aiming to improve treatment convenience and patient compliance.

STRATEGIC SIGNIFICANCE

The CTA approval marks a milestone in advancing the Product into the clinical trial phase. Developing fixed-dose combination nasal sprays entails significant technical challenges, particularly in formulation stability, suspension systems, spray consistency, and scale-up manufacturing. The progress of the Product further validates the Group's execution capabilities in complex nasal spray formulations and drug-device integration.

Furthermore, the Product complements the Group's existing AR and chronic rhinosinusitis (CRS) portfolio, which currently includes azelastine hydrochloride and fluticasone propionate nasal spray (Shu Fei Min®), mometasone furoate nasal spray, and budesonide nasal spray. Collectively, the portfolio covers a broad range of age groups and disease stages, offering accessible, long-term management solutions for upper airway diseases. The Company believes that its integrated capabilities in complex formulations and precision delivery will continue to reinforce its competitive advantages in domestic and global markets.

The Group will maintain active communication with the NMPA and advance subsequent clinical activities in accordance with regulatory requirements.

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. There is no assurance that the approval of CTA will result in the achievement of successful clinical results, the grant of marketing approval or the realization of commercialization. Given such risks and uncertainties, **shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities — from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms — the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening international presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, March 9, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.